Effect of bortezomib on the efficacy of AAV9.SERCA2a treatment to preserve cardiac function in a rat pressure-overload model of heart failure

Gene Therapy

Volumn 21, Issue 4, 2014, Pages 379-386

  Chaanine, A H ^a   Nonnenmacher, M ^a   Kohlbrenner, E ^a   Jin, D ^a   Kovacic, J C ^a   Akar, F G ^a   Hajjar, R J ^a   Weber, T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS 9 PROTEIN SERCA2A; BORTEZOMIB; CARDIOVASCULAR AGENT; MESSENGER RNA; PARVOVIRUS VECTOR; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN; PROTEIN SERCA2A; UNCLASSIFIED DRUG; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 9; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ECHOCARDIOGRAPHY; ENZYME INHIBITION; GENE EXPRESSION; GENETIC TRANSDUCTION; GENOME; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; HELA CELL; HUMAN; IN VIVO STUDY; NEWBORN; NONHUMAN; PRESSURE VOLUME CURVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROTYPE; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; DEPENDOPARVOVIRUS; DISEASE MODEL; DRUG EFFECTS; GENE THERAPY; GENE VECTOR; GENETICS; HEART MUSCLE; METABOLISM; PATHOLOGY;

ADENO-ASSOCIATED VIRUS; RATTUS; RODENTIA;

ANIMALS; BORONIC ACIDS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; HEART FAILURE; HUMANS; MYOCARDIUM; MYOCYTES, CARDIAC; PYRAZINES; RATS; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

EID: 84897573612     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.7     Document Type: Article

References (45)

1. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 2011; 12: 341-355.
2. Gruber K. Europe gives gene therapy the green light. Lancet 2012; 380: e10.
3. Colella P, Auricchio A. Gene therapy of inherited retinopathies: a long and successful road from viral vectors to patients. Hum Gene Ther 2012; 23: 796-807.
4. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365: 2357-2365.
5. Kho C, Lee A, Jeong D, Oh JG, Chaanine AH, Kizana E et al. SUMO1-dependent modulation of SERCA2a in heart failure. Nature 2011; 477: 601-605.
6. Sakata S, Lebeche D, Sakata N, Sakata Y, Chemaly ER, Liang LF et al. Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins. J Mol Cell Cardiol 2007; 42: 852-861.
7. Byrne MJ, Power JM, Preovolos A, Mariani JA, Hajjar RJ, Kaye DM. Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther 2008; 15: 1550-1557.
8. Kawase Y, Ly HQ, Prunier F, Lebeche D, Shi Y, Jin H et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 2008; 51: 1112-1119.
9. 2+-ATPase gene transfer in a beagle heart failure model. Chin Med J (Engl) 2009; 122: 1423-1428.
10. Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009; 15: 171-181.
11. 2+-ATPase in patients with advanced heart failure. Circulation 2011; 124: 304-313.
12. Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr Gene Ther 2011; 11: 321-330.
13. Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JE et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 2007; 13: 419-422.
14. Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther 2005; 5: 285-297.
15. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002; 99: 11854-11859.
16. Michelfelder S, Trepel M. Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv Genet 2009; 67: 29-60.
17. Bartel MA, Weinstein JR, Schaffer DV. Directed evolution of novel adeno-asso-ciated viruses for therapeutic gene delivery. Gene Therapy 2012; 19: 694-700.
18. Nonnenmacher M, Weber T. Intracellular transport of recombinant adeno-asso-ciated virus vectors. Gene Therapy 2012; 19: 649-658.
19. Zhong L, Zhao W, Wu J, Li B, Zolotukhin S, Govindasamy L et al. A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA Synthesis. Mol Ther 2007; 15: 1323-1330.
20. Russell DW, Alexander IE, Miller AD. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc Natl Acad Sci USA 1995; 92: 5719-5723.
21. Zhang T, Hu J, Ding W, Wang X. Doxorubicin augments rAAV-2 transduction in rat neuronal cells. Neurochem Int 2009; 55: 521-528.
22. Hansen J, Qing K, Srivastava A. Adeno-associated virus type 2-mediated gene transfer: altered endocytic processing enhances transduction efficiency in murine fibroblasts. J Virol 2001; 75: 4080-4090.
23. Ju XD, Lou SQ, Wang WG, Peng JQ, Tian H. Effect of hydroxyurea and etoposide on transduction of human bone marrow mesenchymal stem and progenitor cell by adeno-associated virus vectors. Acta Pharmacol Sin 2004; 25: 196-202.
24. Cheng B, Ling C, Dai Y, Lu Y, Glushakova LG, Gee SW et al. Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells. Gene Therapy 2012; 19: 375-384.
25. Denby L, Nicklin SA, Baker AH. Adeno-associated virus (AAV)-7 and-8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation. Gene Therapy 2005; 12: 1534-1538.
26. Douar AM, Poulard K, Stockholm D, Danos O. Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and pro-teasome degradation. J Virol 2001; 75: 1824-1833.
27. Li W, Zhang L, Wu Z, Pickles RJ, Samulski RJ. AAV-6 mediated efficient trans-duction of mouse lower airways. Virology 2011; 417: 327-333.
28. Yan Z, Zak R, Luxton GW, Ritchie TC, Bantel-Schaal U, Engelhardt JF. Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J Virol 2002; 76: 2043-2053.
29. Finn J, Hui D, Downey H, Dunn D, Pien G, Mingozzi F et al. Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction. Mol Ther 2009; 18: 135-142.
30. Mitchell AM, Samulski RJ. Mechanistic insights into the enhancement of adeno-associated virus transduction by proteasome inhibitors. J Virol 2013; 87: 13035-13041.
31. 2+)-ATPase in a rat model of heart failure. Circulation 2001; 104: 1424-1429.
32. Adams J, Elliott P, Bouchard P. Preclinical development of bortezomib (VELCADE). In: Adams J (ed) Proteasome Inhibitors in Cancer Therapy. Humana Press: Totowa, NJ, USA, 2004, pp 233-269.
33. Mariani JA, Smolic A, Preovolos A, Byrne MJ, Power JM, Kaye DM. Augmentation of left ventricular mechanics by recirculation-mediated AAV2/1-SERCA2a gene delivery in experimental heart failure. Eur J Heart Fail 2011; 13: 247-253.
34. Duan D, Yue Y, Yan Z, Yang J, Engelhardt JF. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest 2000; 105: 1573-1587.
35. Johnson JS, Samulski RJ. Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus. J Virol 2009; 83: 2632-2644.
36. Dalkara D, Byrne LC, Lee T, Hoffmann NV, Schaffer DV, Flannery JG. Enhanced gene delivery to the neonatal retina through systemic administration of tyrosine-mutated AAV9. Gene Therapy 2012; 19: 176-181.
37. Qiao C, Yuan Z, Li J, Tang R, Xiao X. Single tyrosine mutation in AAV8 and AAV9 capsids is insufficient to enhance gene delivery to skeletal muscle and heart. Hum Gene Ther Methods 2012; 23: 29-37.
38. Del Monte F, Butler K, Boecker W, Gwathmey JK, Hajjar RJ. Novel technique of aortic banding followed by gene transfer during hypertrophy and heart failure. Physiol Genomics 2002; 9: 49-56.
39. Pacher P, Nagayama T, Mukhopadhyay P, Batkai S, Kass DA. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc 2008; 3: 1422-1434.
40. Porterfield JE, Kottam AT, Raghavan K, Escobedo D, Jenkins JT, Larson ER et al. Dynamic correction for parallel conductance, GP, and gain factor, alpha, in invasive murine left ventricular volume measurements. J Appl Physiol 2009; 107: 1693-1703.
41. Baan J, van der Velde ET, de Bruin HG, Smeenk GJ, Koops J, van Dijk AD et al. Continuous measurement of left ventricular volume in animals and humans by conductance catheter. Circulation 1984; 70: 812-823.
42. Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther 1998; 9: 2745-2760.
43. Grieger JC, Choi VW, Samulski RJ. Production and characterization of adeno-associated viral vectors. Nat Protoc 2006; 1: 1412-1428.
44. Kohlbrenner E, Henckaerts E, Rapti K, Gordon RE, Linden RM, Hajjar RJ et al. Quantification of AAV particle titers by infrared fluorescence scanning of coomassie-stained sodium dodecyl sulfate-polyacrylamide gels. Hum Gene Ther Methods 2012; 23: 198-203.
45. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 1998; 98: 1329-1334.